PLRX News and Press, Pliant Therapeutics Inc. From 03/03/25

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeu...

2025-03-03 11:07:10 ET More on Pliant Therapeutics Pliant Therapeutics: Strange Volatility Pliant stock jumps 28% on bexotegrast study update Canaccord Genuity cuts Pliant to hold on study setback Seeking Alpha’s Quant Rating on Pliant Therapeutics ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommenda...

ASM International NV New York Shares (ASMIY) is expected to report $3.98 for Q4 2024 Sezzle Inc. (SEZL) is expected to report $3.12 for Q4 2024 Fresenius SE & Co. KGaA ADR (FSNUY) is expected to report for Q4 2024 OraSure Technologies Inc. (OSUR) is expected to report $-0.06 for Q...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. (“Pliant” or “the Company”) (NASDAQ: PLRX ) for violations of the securities laws. The investiga...

2025-02-13 10:28:12 ET More on Pliant Therapeutics Pliant Therapeutics: Strange Volatility Canaccord Genuity cuts Pliant to hold on study setback Pliant stock plunges 61% amid study pause, downgrades Seeking Alpha’s Quant Rating on Pliant Therapeutics ...

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial’s independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinde...

2025-02-12 11:09:32 ET More on SPDR S&P 500 ETF Trust: Owning SPHD Instead Of SPY Gets A Big No, Thanks Despite All The Negative News, U.S. And European Stock Markets Continue To Rally Don't Let News Shake You Out Of This Market, Think Judo Trump's tariff...

2025-02-11 11:16:19 ET More on Pliant Therapeutics Pliant Therapeutics: Strange Volatility Pliant stock plunges 61% amid study pause, downgrades Biggest stock movers Monday: MCD, LYFT, BP, X, and more Seeking Alpha’s Quant Rating on Pliant Therapeutics...

2025-02-11 00:31:37 ET Summary Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility. High trading volumes and sharp stock declines occurred before the announcement, indica...